Multiple Sclerosis

Recently Updated
How CBD Changes The Brain To Treat Psychiatric Disorders Last Updated on 2017-07-25 11:56:36 Canna Tech |  July 25, 2017  |  By Jack Woodhouse In a recent study, published in Frontiers in Pharmacology, a group of scientists from the University of São Paulo in Brazil reviewed all the available research in order to learn more about the mechanisms at play when psychiatric disorders are treated with CBD. The study suggests that CBD’s therapeutic effects are caused by a number of acute mechanisms as well as changes in the structure of the brain over time, known as neuroplasticity. CBD has been proven to offer a broad spectrum of therapeutic actions, which include anxiolytic, antipsychotic, antidepressant, anticonvulsant, and neuroprotective effects. These have been studied over a large range of psychiatric and neurodegenerative disorders. Although most of these putative therapeutic properties were initially described in animal models, clinical... More »
CBD Beneficial Effects on Parkinson's, Alzheimer's & MS Last Updated on 2017-07-24 13:28:36 Mannucci C1, Navarra M1, Calapai F1, Spagnolo EV2, Busardò FP3, Da Cas R4, Ippolito FM4, Calapai G1.   Cannabidiol (CBD) is among the major secondary metabolites of Cannabis devoid of the delta-9-tetra-hydrocannabinol psychoactive effects. It is a resorcinol-based compound with a broad spectrum of potential therapeutic properties, including neuroprotective effects in numerous pathological conditions. CBD neuroprotection is due to its antioxidant and antiinflammatory activi-ties and the modulation of a large number of brain biological targets (receptors, channels) involved in the development and maintenance of neurodegenerative diseases. Aim of the present review was to describe the state of art about the pre-clinical research, the potential use and, when existing, the clinical evidence related to CBD in the neurological field. Collection of all the... More »
Marijuana Compound Shows Promise In The Fight Against Multiple Sclerosis Last Updated on 2017-07-19 13:54:45   CBD is of particular interest to the TAU researchers because it offers medicinal benefits without the controversial mind-altering effects of THC. CBD was shown to help treat MS-like symptoms in mice in a 2011 TAU study.   April Flowers for - Your Universe Online Multiple Sclerosis, an inflammatory disease in which the immune system attacks the nervous system, results in a wide range of debilitating motor, physical and mental problems. Scientists still have no idea why someone gets the disease or how to treat it. A new study, led by Tel Aviv University's Dr. Miriam and Sheldon G. Adelson Center for the Biology of Addictive Diseases and Sackler Faculty of Medicine, reveals some of the chemical compounds found in marijuana can help treat MS-like diseases in mice. The research team, which included scientists from Tel Aviv University and the Weizmann... More »
Study: Inhaled Cannabis Reduces Symptoms In Patients With Treatment-Resistant Multiple Sclerosis Last Updated on 2017-07-19 13:47:34 Thursday, 17 May 2012 San Diego, CA: Cannabis inhalation mitigates spasticity and pain in patients with treatment-resistant multiple sclerosis (MS), according to clinical trial data published online this week in the Journal of the Canadian Medical Association (CMAJ). Investigators at the University of California, San Diego assessed the use of inhaled cannabis versus placebo in 30 patients with MS who were unresponsive to conventional treatments. Authors reported that cannabis administration resulted in a decrease in subjects' spasticity, as measured on the modified Ashworth scale, and reduced patients' pain scores on a visual analogue scale. "Smoked cannabis was superior to placebo in symptom and pain reduction in patients with treatment-resistant spasticity," authors concluded. Investigators cautioned that cannabis-inhalation was also negatively associated with... More »
THC:CBD spray and MS spasticity symptoms: data from latest studies. Last Updated on 2017-07-19 13:44:18 U.S. National Library of Medicine New clinical experience with 9-delta-tetrahydocannabinol (THC) and cannabidiol (CBD) oromucosal spray (Sativex®) involving more than an additional 1,000 patients with MS spasticity (approximately 150 in clinical studies and 900 in post-marketing surveillance studies) have become available in 2013 and are reviewed. A randomized, placebo controlled long-term follow-up clinical trial with THC:CBD spray versus placebo demonstrated that it was not associated with cognitive decline, depression or significant mood changes after 12 months of treatment. Furthermore, in a prospective observational pilot study involving 33 patients (60% female) aged 33-68 years and a mean disease duration of 6.6 years, THC:CBD oromucosal spray did not adversely influence standard driving ability in patients with moderate to severe MS spasticity. Other new long term... More »